The introduction of IFRS 2 in 2004 generated considerable debate about the best approach for handling ‘share-based payments’ (SBP). While it is clearly a cost to shareholders, which should be included in the statutory reporting lines through the P&L account, the question arose as to whetherit should be part of our underlying EBIT calculation.

01 Aug 2019
THE MONTHLY August 2019
AJ Bell Plc (AJB:LON), 434 | Allergy Therapeutics plc (AGY:LON), 6.2 | Arbuthnot Banking Group PLC (ARBB:LON), 940 | City of London Investment Group PLC (CLIG:LON), 362 | DP Poland PLC (DPP:LON), 9.2 | Gateley (Holdings) Plc (GTLY:LON), 138 | Genedrive Plc (GDR:LON), 2.1 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 386 | Palace Capital plc (PCA:LON), 228 | Primary Health Properties PLC (PHP:LON), 94.1 | R.E.A. Holdings plc (RE:LON), 72.5 | RM Infrastructure Income PLC GBP (RMII:LON), 72.0 | Shield Therapeutics Plc (STX:LON), 3.6 | Surface Transforms PLC (SCE:LON), 0.3 | Tissue Regenix Group plc (TRX:LON), 52.1 | Titon Holdings Plc (TON:LON), 75.0 | Urban Logistics REIT plc (SHED:LON), 117 | Volta Finance Limited (VTA:LON), 620 | Warpaint London PLC (W7L:LON), 410 | ValiRx PLC (VAL:LON), 0.7

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
THE MONTHLY August 2019
AJ Bell Plc (AJB:LON), 434 | Allergy Therapeutics plc (AGY:LON), 6.2 | Arbuthnot Banking Group PLC (ARBB:LON), 940 | City of London Investment Group PLC (CLIG:LON), 362 | DP Poland PLC (DPP:LON), 9.2 | Gateley (Holdings) Plc (GTLY:LON), 138 | Genedrive Plc (GDR:LON), 2.1 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 386 | Palace Capital plc (PCA:LON), 228 | Primary Health Properties PLC (PHP:LON), 94.1 | R.E.A. Holdings plc (RE:LON), 72.5 | RM Infrastructure Income PLC GBP (RMII:LON), 72.0 | Shield Therapeutics Plc (STX:LON), 3.6 | Surface Transforms PLC (SCE:LON), 0.3 | Tissue Regenix Group plc (TRX:LON), 52.1 | Titon Holdings Plc (TON:LON), 75.0 | Urban Logistics REIT plc (SHED:LON), 117 | Volta Finance Limited (VTA:LON), 620 | Warpaint London PLC (W7L:LON), 410 | ValiRx PLC (VAL:LON), 0.7
- Published:
01 Aug 2019 -
Author:
Martin Hall -
Pages:
34 -
The introduction of IFRS 2 in 2004 generated considerable debate about the best approach for handling ‘share-based payments’ (SBP). While it is clearly a cost to shareholders, which should be included in the statutory reporting lines through the P&L account, the question arose as to whetherit should be part of our underlying EBIT calculation.